Posted by Michael Wonder on 18 Aug 2019
Novartis CEO says FDA process could have been handled better
17 August 2019 - Novartis AG Chief Executive Officer Vas Narasimhan said the company could have handled a furore surrounding its Zolgensma gene therapy better.
Narasimhan, who became CEO of the pharmaceutical manufacturer last year, made the comment in a company call with 12,000 managers, according to newspaper Schweiz am Wochenende.
Looking back, Narasimhan said he recognised opportunities where Novartis could have handled the situation better. Narasimhan said he is not perfect as a CEO and “we will all keep working on it.”
